Celldex discontinues barzolvolimab development in atopic dermatitis after Phase 2 results show no significant improvement in itch, EASI or IGA endpoints.
Written By: Anamika Koshti, PharmD
Reviewed By: Pharmacally Editorial Team
Celldex Therapeutics reported on November 19, 2026, that its Phase 2 study of barzolvolimab in patients with moderate to severe atopic dermatitis (AD) failed to meet its primary and key secondary efficacy endpoints. Because the observed improvements fell short of its internal threshold for continued development, the company confirmed it would discontinue barzolvolimab development in AD.
Study Design: Testing Mast Cell Depletion Against Itch
The Phase 2 trial (NCT06727552) enrolled 131 patients across 28 US centres, randomising participants in a 1:1:1 ratio to receive subcutaneous barzolvolimab 150 mg or 300 mg every four weeks (Q4W), each following an initial 450 mg loading dose, or placebo. After a 16-week placebo-controlled period, patients entered a 16-week active treatment period in which barzolvolimab recipients remained on their assigned regimens, while placebo recipients were re-randomised to either active dose.
The primary endpoint was the percentage change from baseline in the weekly average of daily Peak Pruritus Numerical Rating Scale (PP-NRS) scores at Week 16 compared with placebo. Key secondary endpoints included changes in the Eczema Area and Severity Index (EASI) and the proportion of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1.
Barzolvolimab is a first-in-class humanised monoclonal antibody targeting the KIT receptor, which is essential for mast cell survival and function, thereby inducing systemic mast cell depletion. The study was designed with 80% statistical power and a type I error rate of 0.1.
Key Results: Neither Dose Met the Primary Endpoint
At Week 16, neither barzolvolimab regimen achieved a statistically significant improvement in PP-NRS scores over placebo.
- Placebo: Demonstrated a 19.5% mean reduction in PP-NRS scores.
- Barzolvolimab 300 mg Q4W: Showed a 29.2% mean reduction, representing a 9.7 percentage-point greater reduction than placebo (90% CI: −21.7 to 2.4; p=0.187).
- Barzolvolimab 150 mg Q4W: Demonstrated a 16.2% mean reduction, corresponding to a 3.3 percentage-point difference in favour of placebo (90% CI: −8.7 to 15.3; p=0.651).
Neither dose demonstrated a statistically significant improvement over placebo. Key secondary endpoints, including EASI improvement and the proportion of patients achieving IGA 0 or 1, also failed to meaningfully differentiate from placebo. Celldex did not disclose numerical values for these secondary measures in its topline announcement.
Extended Treatment and Pharmacodynamic Findings
Continuing treatment through Week 32 produced no additional clinical improvement across the primary or key secondary endpoints, indicating that prolonged exposure did not establish a meaningful therapeutic advantage.
Despite the lack of demonstrated clinical efficacy, both doses produced rapid and profound suppression of circulating serum tryptase, indicative of systemic mast cell depletion. Tryptase levels fell sharply following the 450 mg loading dose and remained suppressed throughout treatment. These findings demonstrated pharmacodynamic activity that did not translate into statistically significant improvement in the measured clinical endpoints.
Safety and Tolerability
Barzolvolimab was well tolerated across both dosing groups, with the 450 mg loading dose followed by Q4W treatment demonstrating a favourable safety profile consistent with earlier clinical studies. Detailed adverse-event rates were not included in the company’s topline announcement.
Clinical Interpretation: Target Engagement Without Clinical Benefit
The Phase 2 findings indicate that systemic mast cell depletion with the evaluated barzolvolimab regimens was insufficient to produce meaningful clinical improvement in moderate to severe AD. While mast cells contribute to AD pathology, Celldex interpreted the findings as suggesting that they may not be a primary driver of the disease.
However, the results do not establish that mast cells have no meaningful role in AD. Rather, they highlight the limitations of the evaluated KIT-directed mast cell depletion approach in this particular disease setting. Based on the overall efficacy findings and its internal development criteria, Celldex has discontinued barzolvolimab development in AD.
Attention Returns to Chronic Urticaria Programme
The AD discontinuation does not affect Celldex’s ongoing barzolvolimab programme in chronic urticaria. In September 2026, the company announced that its Phase 3 EMBARQ-CSU1 (NCT06445023) and EMBARQ-CSU2 (NCT06455202) studies met their primary and all key secondary endpoints at Week 12 in chronic spontaneous urticaria (CSU).
Complete response rates, defined as a Urticaria Activity Score over 7 days (UAS7) of 0, ranged from 42.1% to 45.7% across barzolvolimab treatment groups, compared with 9.3% and 12.6% in the respective placebo groups. Treatment continues through 52 weeks, with a Biologics License Application (BLA) submission planned for 2027.
Celldex is also enrolling patients in its Phase 3 EMBARQ-ColdU and SD study (NCT07266402), evaluating barzolvolimab in cold urticaria and symptomatic dermographism. The company expects to announce additional indications by the end of 2026.
Together, the contrasting outcomes in AD and CSU highlight the importance of disease-specific mast cell biology in evaluating the therapeutic potential of KIT-directed mast cell depletion.
Reference
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis, Celldex, 19 November 2026
A Study of Barzolvolimab in Patients with Atopic Dermatitis, ClinicalTrials.gov ID NCT06727552
About the Writer
Anamika Koshti (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, and evidence-based medicine. She has authored peer-reviewed publications on Alzheimer’s disease and PCOS, presented research at national conferences, and gained hands-on experience in medical content development and clinical data interpretation. She is committed to translating complex medical research into accurate, accessible content for healthcare professionals and patients.
